Abstract Library

#4496 ATRX, DAXX, and menin immunohistochemistry identify prognostic relevant non-functioning neuroendocrine tumours subgroups

Introduction: Non-functioning pancreatic neuroendocrine tumours (NF-pNETs) are rare tumours with a variable prognosis. Recent studies have identified prognostic subgroups based on ATRX, DAXX and MEN1 mutations along with chromosomal aneuploidies.

Conference:

Presenting Author: Verschuur A

Authors: Verschuur A, Jairam J, Eldem B, Singhi A, Hackeng W,

Keywords: pancreatic neuroendocrine tumour, ATRX, DAXX, MEN1, menin, biomarker,

#4133 Clinical impact and prognosis of patients with Si-NET and bone metastases – Do they matter?

Introduction: The prevalence of bone metastases (BM) in small intestinal neuroendocrine tumors (Si-NET) ranges from 5 to 23 %.

Conference:

Presenting Author: Wedin M

Authors: Wedin M, Daskalakis K, Tiensuu Janson E, Sundin A, Wallin G,

Keywords: bone metastases, si-net, Neuroendocrine Neoplasm,

#3735 Longitudinal changes in Ki-67 index in a prospective cohort of pancreatic neuroendocrine tumors

Introduction: The biology of pancreatic neuroendocrine tumors (panNET) can change over time. In retrospective cohorts, many panNETs showed longitudinal increases in Ki-67 index leading to a higher tumor grade and poor survival. However, data from prospective studies are lacking, and non-invasive methods of determining tumor grade progression are needed in order to monitor and guide further treatment.

Conference:

Presenting Author: Mollazadegan K

Authors: Mollazadegan K, Botling J, Welin S, Zhang L, Eriksson B,

Keywords: neuroendocrine tumor, pancreas, high-grade, poor prognosis, biomarker, Ki-67,

#3721 No multiple endocrine neoplasia type 1 (MEN1) Patient died from pancreaticoduodenal neuroendocrine tumor – Results from long-term follow-up of the Uppsala model of early diagnosis and treatment

Introduction: Progression of pancreaticoduodenal neuroendocrine tumor (P-NET) disease is the main death cause among MEN1 carriers. Although surgery is the only cure, indications vary substantially between centers. The Uppsala model of MEN1 management encompasses early diagnosis and treatment, aiming at lifelong malignancy prevention with preserved endocrine function. During three decades, all MEN1 patients harbouring P-NETs of at least 1 cm have been considered for surgery.

Conference:

Presenting Author:

Authors: Bajic D, Kjaer J, Welin S, Norlén O, Öberg K,

Keywords: multiple endocrine neoplasia type 1, pancreatic neuroendocrine tumor, indication for surgery, malignancy prevention,

#3550 Randomized open label phase III study comparing the efficacy and safety of Everolimus followed by chemotherapy with Streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)

Introduction: STZ-5FU and everolimus are frontline options for systemic treatment in patients with advanced and progressive pancreatic neuroendocrine tumors (panNETs). Switch between both upon progression is a common strategy, but the best sequence is not yet well established.

Conference:

Presenting Author: Salazar R

Authors: Capdevila J, Tafuto S, Vestermark L, Teulé A, Garcia-Carbonero R,

Keywords: pNET, everolimus, streptozotocin, 5FU, randomized trial,